Patents by Inventor Theo N. Kirkland

Theo N. Kirkland has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8821884
    Abstract: The invention provides compositions and methods for the targeted bacteriostatic and antibacterial agents and for treatment of sepsis caused by infectious diseases, such as bacterial and fungal diseases. In one aspect, the invention provides methods and compositions for decreasing the levels of LPS in the circulation of an individual, e.g., a human patient with sepsis, e.g., gram negative septic shock. In one aspect, the invention is directed to chimeric proteins comprising the MD-2 polypeptide and an opsinizing agent, e.g., antibody Fc domains, or equivalent. In one aspect, the invention is directed to chimeric proteins comprising fragments or altered form of MD-2 polypeptide and an opsinizing agent, e.g., antibody Fc domains, or equivalent. The invention also provides pharmaceutical compositions comprising the chimeric polypeptides of the invention, and methods of making and using them, including methods for ameliorating or preventing sepsis.
    Type: Grant
    Filed: July 27, 2005
    Date of Patent: September 2, 2014
    Assignee: The Regents of the University of California
    Inventors: Theo N. Kirkland, III, Sunganya Viriyakosol
  • Publication number: 20080118504
    Abstract: The invention provides compositions and methods for the targeted bacteriostatic and antibacterial agents and for treatment of sepsis caused by infectious diseases, such as bacterial and fungal diseases. In one aspect, the invention provides methods and compositions for decreasing the levels of LPS in the circulation of an individual, e.g., a human patient with sepsis, e.g., gram negative septic shock. In one aspect, the invention is directed to chimeric proteins comprising the MD-2 polypeptide and an opsinizing agent, e.g., antibody Fc domains, or equivalent. In one aspect, the invention is directed to chimeric proteins comprising fragments or altered form of MD-2 polypeptide and an opsinizing agent, e.g., antibody Fc domains, or equivalent. The invention also provides pharmaceutical compositions comprising the chimeric polypeptides of the invention, and methods of making and using them, including methods for ameliorating or preventing sepsis.
    Type: Application
    Filed: July 27, 2005
    Publication date: May 22, 2008
    Inventors: Theo N. Kirkland, Sunganya Viriyakosol
  • Patent number: 7262027
    Abstract: The present invention provides compositions of novel polypeptides and polynucleotides encoding the polypeptides, which polypeptides are useful for generating an immunological response in an individual and in therapeutic application of Coccidioides spp. infection.
    Type: Grant
    Filed: March 3, 2004
    Date of Patent: August 28, 2007
    Assignees: Medical College of Ohio, The Regents of the University of California, United States of America Represented by the Department of Veterans Affairs
    Inventors: Garry T. Cole, Jieh-Juen Yu, Jianmin Xue, Chiung-Yu Hung, Kalpathi R. Seshan, Theo N. Kirkland, III
  • Publication number: 20040181046
    Abstract: The present invention provides compositions of novel polypeptides and polynucleotides encoding the polypeptides, which polypeptides are useful for generating an immunological response in an individual and in therapeutic application of Coccidioides spp. infection.
    Type: Application
    Filed: March 3, 2004
    Publication date: September 16, 2004
    Applicant: MEDICAL COLLEGE OF OHIO
    Inventors: Garry T. Cole, Jieh-Juen Yu, Jianmin Xue, Chiung-Yu Hung, Kalpathi R. Seshan, Theo N. Kirkland
  • Publication number: 20030114377
    Abstract: Described are methods and novel therapeutics for treating CD14-mediated diseases, especially sepsis and septic shock. The methods and compounds are founded on principles of structural mimicry of the innate compound. Changes to the innate compound are described that result in unexpected properties useful for blocking or ameliorating the harmful effects of systemic infection by microbes. Diagnostic applications and product-by-process claims are also contemplated based on the same underlying principle and observation.
    Type: Application
    Filed: September 20, 2002
    Publication date: June 19, 2003
    Inventors: Theo N. Kirkland, Suganya Viriyakosol